Exact Mass: 1028.560926

Exact Mass Matches: 1028.560926

Found 24 metabolites which its exact mass value is equals to given mass value 1028.560926, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Mivacurium

Mivacurium mixture of isomers

C58H80N2O14+2 (1028.560926)


D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist

   
   

PIP(20:0/20:3(8Z,11Z,14Z)-2OH(5,6))

{[(1R,3S)-3-({[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-(icosanoyloxy)propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C49H90O18P2 (1028.5602099999999)


PIP(20:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of eicosanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/20:0)

{[(1R,3S)-3-({[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-(icosanoyloxy)propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C49H90O18P2 (1028.5602099999999)


PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/20:0) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:3(8Z,11Z,14Z)-2OH(5,6)/20:0), in particular, consists of one chain of 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of eicosanoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:2(13Z,16Z)/18:1(12Z)-2OH(9,10))

{[(1R,3S)-3-({[(2R)-2-{[(9S,10S,12Z)-9,10-dihydroxyoctadec-12-enoyl]oxy}-3-[(13Z,16Z)-docosa-13,16-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C49H90O18P2 (1028.5602099999999)


PIP(22:2(13Z,16Z)/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:2(13Z,16Z)/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of 13Z,16Z-docosadienoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(18:1(12Z)-2OH(9,10)/22:2(13Z,16Z))

{[(1R,3S)-3-({[(2R)-3-{[(9R,10R,12Z)-9,10-dihydroxyoctadec-12-enoyl]oxy}-2-[(13Z,16Z)-docosa-13,16-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C49H90O18P2 (1028.5602099999999)


PIP(18:1(12Z)-2OH(9,10)/22:2(13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(18:1(12Z)-2OH(9,10)/22:2(13Z,16Z)), in particular, consists of one chain of 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 13Z,16Z-docosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   
   

oleanolic acid 3-O-alpha-L-arabinopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->2)[beta-D-glucopyranosyl(1->4)]-alpha-L-arabinopyranoside|raddeanoside R23

oleanolic acid 3-O-alpha-L-arabinopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->2)[beta-D-glucopyranosyl(1->4)]-alpha-L-arabinopyranoside|raddeanoside R23

C52H84O20 (1028.5555664)


   

3-O-alpha-L-rhamnopyranosyl(1->2)-alpha-L-arabinopyranosyl-oleanolic acid 28-O-beta-D-xylopyranosyl(1->6)-beta-D-glucopyranosyl ester

3-O-alpha-L-rhamnopyranosyl(1->2)-alpha-L-arabinopyranosyl-oleanolic acid 28-O-beta-D-xylopyranosyl(1->6)-beta-D-glucopyranosyl ester

C52H84O20 (1028.5555664)


   

olean-12-ene-28-oic-3-O-(alpha-L-arabinofuranosyl 1-2) (alpha-L-arabinofuranosyl 1-2-O-alpha-L-rhamnopyranosyl 1-4)-beta-D-glucopyranoside

olean-12-ene-28-oic-3-O-(alpha-L-arabinofuranosyl 1-2) (alpha-L-arabinofuranosyl 1-2-O-alpha-L-rhamnopyranosyl 1-4)-beta-D-glucopyranoside

C52H84O20 (1028.5555664)


   

3-O-[beta-D-xylopyranosyl-(1->3)-alpha-L-rhamnopyranosy-(1->2)-alpha-L-xylopyranosyl]olean-12-ene 28-O-[beta-D-glucopyranosyl] ester|lycicoside II

3-O-[beta-D-xylopyranosyl-(1->3)-alpha-L-rhamnopyranosy-(1->2)-alpha-L-xylopyranosyl]olean-12-ene 28-O-[beta-D-glucopyranosyl] ester|lycicoside II

C52H84O20 (1028.5555664)


   
   
   

Mivacurium

(1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium

C58H80N2O14++ (1028.560926)


Mivacurium is only found in individuals that have used or taken this drug. It is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.

   
   
   

PIP(22:2(13Z,16Z)/18:1(12Z)-2OH(9,10))

PIP(22:2(13Z,16Z)/18:1(12Z)-2OH(9,10))

C49H90O18P2 (1028.5602099999999)


   

PIP(18:1(12Z)-2OH(9,10)/22:2(13Z,16Z))

PIP(18:1(12Z)-2OH(9,10)/22:2(13Z,16Z))

C49H90O18P2 (1028.5602099999999)


   

Mivacurium

Mivacurium

C58H80N2O14+2 (1028.560926)


D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist

   

(4as,6as,6br,8ar,10s,12ar,12br,14br)-10-{[(2s,3r,4s,5s)-3-{[(2s,3r,4r,5s,6s)-4-{[(2s,3r,4s,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,10s,12ar,12br,14br)-10-{[(2s,3r,4s,5s)-3-{[(2s,3r,4r,5s,6s)-4-{[(2s,3r,4s,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C52H84O20 (1028.5555664)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10-{[3-({3,5-dihydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10-{[3-({3,5-dihydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C52H84O20 (1028.5555664)


   

(2s,3r,4s,5s)-3-{[(2s,3r,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl (4as,6as,6br,8ar,10s,12ar,12br,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

(2s,3r,4s,5s)-3-{[(2s,3r,4s,5r,6s)-3,4-dihydroxy-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl (4as,6as,6br,8ar,10s,12ar,12br,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C52H84O20 (1028.5555664)